An interventional study of Internet-Based Glucose Monitoring System and Normal Medication Positive Control in Type 2 Diabetes Mellitus, sponsored by Endocrine Research Society. Completed at 1 site in Canada. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-09-21.
Sponsored by Endocrine Research Society · Not applicable, Interventional, and Supportive care
Managing blood sugar levels is important for patients with type 2 diabetes (T2DM) to minimize health problems and complications. One way for patients to notify doctors and receive feedback about their blood sugar management is through an online system. As Internet-based glucose monitoring systems (IBGMS) have already been shown to be effective, the investigators hypothesize that IBGMS is effective as an intervention even when limiting feedback to non-medicine related changes.
Purpose:
To determine the effectiveness of an Internet-based glucose monitoring system (IBGMS) in the absence of medication changes.
Hypothesis:
IBGMS without medication changes is comparable to conventional medication at reducing HbA1c levels over 8% in patients with T2DM.
Justification:
Patients with T2DM having elevated HbA1c levels may be prescribed additional medications to help manage their blood sugar levels, which include oral hypoglycemic agents and/or insulin. As IBGMS has been shown to be effective in reducing HbA1c in T2DM, there is an opportunity to determine whether if this system could be used as an alternative to medication.
The benefits would include reduced side effects as a result of substituting for the effects of medication, as well as reduced financial costs associated with acquiring medication.
Considering that IBGMS increases the frequency at which patients receive feedback to change medications as compared to typical treatment, the risk is as typical for a patient opting for no medication changes for the same period of time.
Research Method: 120 patients with T2DM satisfying the inclusion criteria will be recruited and have baseline HbA1c established through regular lab blood tests. They will be randomized into one of two groups, one that will be trained to use IBGMS and one control group going on an appropriate additional medication.
The IBGMS group will be asked to report their blood sugars to their endocrinologist biweekly and receive feedback for each report. No medication changes will be offered in the feedback, but lifestyle or dietary recommendations may be included.
The control group will be asked to take their new medications as indicated by their endocrinologist.
Both groups will have followup visits with their endocrinologist at 3 and 6 months, and will also have blood tests done at those time points checking their HbA1c levels.
The effectiveness of both interventions will be evaluated individually and against each other.
For the IBGMS group, a rescue secondary endpoint occurs if a subject maintains an HbA1c level at or greater than 8% after 3 months; the subject will be withdrawn from the study and put under standard care.
10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.
This study's enrollment of 60 is below the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →Endocrine Research Society is the lead sponsor of 11 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and provide feedback limited to non-medicine related comments and suggestions.
Other: Internet-Based Glucose Monitoring System
The subjects will be prescribed a new medication as appropriate for normal therapy. This group will receive no biweekly feedback nor require to report online, but will see the endocrinologist every 3 months up to 6 months.
Drug: Normal Medication Positive Control
Also known as: Internet Blood Glucose Monitoring System, Remote Blood Glucose Monitoring System
HbA1c Levels before and after intervention
Compare HbA1c Levels before and after intervention for both arms, as well as the difference in HbA1c Levels between arms.
Time frame: 6 months
The secondary endpoint include severe hypoglycemia defined as requiring external aid (hospital or other).
Time frame: 6 months
A secondary endpoint includes adverse events such as unplanned hospitalizations for any cause that last more than 24 hours
Time frame: 6 months
HbA1c levels remain at 8% or higher
Time frame: 3 months
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Endocrine Research Society